Semax 5mg

What is Semax? Semax 5mg is a synthetic peptide derived from the 4-10 fragment of the adrenocorticotropic hormone (ACTH). Developed in Russia during the 1980s, this neuropeptide was initially designed to prevent and treat circulatory disorders and acute cerebral hypoxia, often resulting from traumatic brain injuries. Although Semax 5 mg has not yet received FDA approval, research has demonstrated its potential benefits. Studies suggest that Semax may enhance memory, improve mental clarity, and elevate dopamine levels in the brain. It is also thought to have neuroprotective effects. In clinical trials, Semax 5mg has shown promise. For example, in a study with 100 participants, Semax was found to accelerate the recovery of brain functions when added to standard treatments. Another trial indicated that Semax 5mg could potentially reduce brain damage and lower the risk of future strokes in patients with compromised cerebral blood flow.  

Semax
CAS Number	4037-01-8
Molar Mass	813.93 g/mol
Molecular Formula	C37H51N9O10S
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro

    Semax Overview Semax 5mg is a neuropeptide originally developed in Russia during the 1980s to address circulatory issues such as heart attacks, strokes, and high blood pressure. While it is approved for clinical use in Russia, it has not yet received approval in other countries. Research suggests that Semax may offer several potential benefits, including increasing dopamine levels in the brain, enhancing blood flow, and improving memory. Additionally, a 2007 animal study indicated that Semax could potentially aid in the treatment of depression by boosting the activity of dopamine and serotonin in the brain.

---

https://pubmed.ncbi.nlm.nih.gov/11517472/